Cardlytics Reports 2025 Annual Results with Revenue Decline, Major Goodwill Impairment, and Strategic Bridg Divestiture

summarizeSummary

Cardlytics, Inc. reported a 16% revenue decline for 2025, alongside a significant $49.1 million goodwill impairment on its core U.S. platform, and the strategic divestiture of its Bridg platform for up to $30 million in stock.

check_boxKey Events

• 2025 Financial Performance

  Reported a 16% revenue decline to $233.3 million, but significantly reduced net loss to $103.5 million (from $189.3 million in 2024) and achieved positive operating cash flow of $9.3 million (from a negative $8.8 million in 2024). Adjusted EBITDA improved to $10.1 million from $2.5 million.

• Strategic Divestiture of Bridg Platform

  Entered into a definitive agreement on January 23, 2026, to sell its Bridg platform for $27.5 million to $30 million in PAR Technology Corporation common stock. This transaction is highly material, representing over 50% of Cardlytics' current market capitalization.

• Major Goodwill Impairment

  Recognized a $49.1 million goodwill impairment on the Cardlytics platform in the U.S. during 2025, attributed to a slowdown in the economy, decreased consumer spending, and a sustained decline in stock price. This follows a $117.8 million impairment on the Bridg platform in 2024.

• Loss of Key Financial Institution Partner

  The relationship with Bank of America, previously one of the top three FI partners, ended on February 16, 2026, impacting a significant portion of the company's Partner Share.

auto_awesomeAnalysis

The 2025 annual report reveals a company undergoing significant transformation and facing headwinds. While net loss improved and operating cash flow turned positive, these gains were overshadowed by a 16% year-over-year revenue decrease and a substantial $49.1 million goodwill impairment on the core Cardlytics U.S. platform, indicating challenges in its primary business. The strategic sale of the Bridg platform for up to $30 million in PAR common stock, a value representing over 50% of Cardlytics' current market capitalization, marks a major shift in focus. This divestiture, coupled with the termination of the relationship with Bank of America (a top-three financial institution partner), signals a period of significant restructuring and potential uncertainty regarding future growth and partnerships. Investors should monitor the integration of the new CFO, the impact of the Bridg divestiture on the remaining business, and the company's ability to stabilize revenue and secure new partnerships following the loss of Bank of America.